Postnatal Care of Woman with Rheumatic Diseases

Mouyis, Maria

doi:10.1007/s12325-020-01448-1

Cited by 4 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Postpartum monitoring is imperative, recognizing that many disease flares and thromboembolic events manifest within the initial six months post-delivery ( 98 ). Breastfeeding is encouraged; however, a personalized discussion regarding the safety of medications during lactation is crucial.…”

Section: Delivery and Postpartum Carementioning

confidence: 99%

Lupus nephritis: management challenges during pregnancy

Gholizadeh Ghozloujeh,

Singh,

Jhaveri

et al. 2024

Front. Nephrol.

View full text Add to dashboard Cite

Lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), leads to significant kidney inflammation and damage and drastically increases mortality risk. Predominantly impacting women in their reproductive years, LN poses specific risks during pregnancy, including pre-eclampsia, growth restrictions, stillbirth, and preterm delivery, exacerbated by lupus activity, specific antibodies, and pre-existing conditions like hypertension. Effective management of LN during pregnancy is crucial and involves carefully balancing disease control with the safety of the fetus. This includes pre-conception counseling and a multidisciplinary approach among specialists to navigate the complexities LN patients face during pregnancy, such as distinguishing LN flare-ups from pregnancy-induced conditions. This review focuses on exploring the complex dynamics between pregnancy and LN, emphasizing the management difficulties and the heightened risks pregnant women with LN encounter.

show abstract

Section: Delivery and Postpartum Carementioning

confidence: 99%

Lupus nephritis: management challenges during pregnancy

Gholizadeh Ghozloujeh,

Singh,

Jhaveri

et al. 2024

Front. Nephrol.

View full text Add to dashboard Cite

show abstract

“…Пациенткам с РЗ необходимо полноценно ухаживать за новорожденными, иметь силы и возможность начать и продолжить лактацию, сохранять физическую активность. Знания о течении заболевания после родов, предикторах увеличения его активности необходимы для правильного выбора тактики терапии, в том числе на фоне лактации и адекватной курации пациенток [2]. Среди РЗ активность после родов достаточно хорошо изучена при ревматоидном артрите (послеродовое обострение имеет место у 50-90% больных) и системной красной волчанке (обос трение у 35-70% больных) [1].…”

Section: Introductionunclassified

Activity of ankylosing spondylitis in women within one year after childbirth

Krichevskaya

Дубинина

Ильиных

et al. 2022

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. To assess the dynamics of activity of ankylosing spondylitis (AS) during the year after childbirth, to identify predictors of high activity. Materials and methods. 75 pregnant with confirmed AS (modified New York criteria, 1984) were included for prospective observation. Of these, 44 women were followed up for 1 year after delivery. The average age of the patients was 32.55.8 years, the duration of the disease was 149.096.3 months. Lactation was established in 40 women and the duration was 10 [4; 12] months. Results. The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) at 1, 6 and 12 months after giving birth was 2.4 [1.4; 4.2], 2.6 [1.4; 4.4] and 2.7 [1.5; 4.1], respectively (p0.05). ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score C-reactive protein) was 2.0 [1.2; 2.7], 1.9 [1.4; 2.5] and 1.7 [1.3; 2.3], respectively (p0.05). There were no differences between the values of BASDAI, ASDAS-CRP between women with and without lactation. Predictors of high AS activity (BASDAI4) 1 month after delivery were: BASDAI4 in the 1st (odds ratio OR 8.1; 95% confidence interval CI 1,837,0) and 2nd trimesters of pregnancy (OR 5.1, 95% CI 1.220.6); NRS back pain 4 in the 2nd trimester (OR 4.3, 95% CI 1.117.2); cancellation of biological disease-modifying antirheumatic drugs therapy in the 1st trimester of pregnancy (OR 21.0, 95% CI 1.0440.9). Predictors of high AS activity in 6 months after delivery were: BASDAI4 in the 1st (OR 6.5, 95% CI 1.528.7), in the 2nd (OR 6.7, 95% CI 1.627.8) and in the 3rd trimesters of pregnancy (OR 8.7, 95% CI 1.938.6); high activity in 1 month after delivery (OR 4.0, 95% CI 1.015.9). Conclusion. AS activity remains stable for 1 year after delivery. High AS activity during pregnancy was a risk factor for high activity within 6 months after delivery.

show abstract

“…Although some studies indicate that PSO, PsA, and RA disease activity may improve during pregnancy [11][12][13][14][15], and deteriorate after pregnancy for patients with axSpA or ankylosing spondylitis (AS) [16,17], the course of disease in individual patients is unpredictable. Furthermore, disease flares after delivery are frequently reported among women with rheumatic diseases [18]. Due to the association between uncontrolled disease activity and the health of the mother and child, patients with active disease during pregnancy require effective therapeutic interventions.…”

Section: Introductionmentioning

confidence: 99%

Treatment Patterns and Resource Utilization of Pregnant Women with Inflammatory Rheumatic Diseases or Psoriasis in Germany: A Claims Database Analysis

et al. 2021

View full text Add to dashboard Cite

Background: Uncontrolled inflammatory disease activity can impact pregnancy outcomes and the health of the mother and child. This retrospective claims database analysis assessed treatment patterns before, during, and after pregnancy among women with inflammatory rheumatic disease (IRD; axial spondyloarthritis [axSpA], psoriatic arthritis [PsA], and rheumatoid arthritis [RA]) or psoriasis (PSO) in Germany. Methods: Data were extracted from the BARMER sickness fund (2013)(2014)(2015)(2016)(2017). Pregnant women (18-45 years) with documented IRD or PSO diagnoses were compared with age-matched controls from the same database for the analysis of patient characteristics, healthcare resource utilization, and pharmacological treatment during pregnancy. Reported measures included the proportion of women with pharmacological prescriptions or hospitalization/new prescription of corticosteroids or biologics in the 180 days before pregnancy, during pregnancy, and 180 days after delivery. Pre-specified prescription categories (such as disease-specific drugs [not including biologics]) were identified by anatomical therapeutic chemical classification codes. Extrapolated values to the German statutory health insurance population are reported. Results: Overall, 2702 pregnant women with IRD (axSpA: 1063; PsA: 660; RA: 979) and 6527 with PSO were identified. The proportion of women with IRD receiving prescriptions for disease-specific drugs reduced during pregnancy and remained stable after delivery (before: 15.0%; during: 9.0%; after: 9.7%). The proportion of women with PSO receiving prescriptions for disease-specific drugs was low (before: 0.6%; during: 0.3%; after: 0.1%). The proportion of women with hospitalization/new prescription of corticosteroids or biologics decreased during pregnancy, compared with pre-pregnancy, and increased after delivery in women with IRD

show abstract

Postnatal Care of Woman with Rheumatic Diseases

Cited by 4 publications

References 39 publications

Lupus nephritis: management challenges during pregnancy

Lupus nephritis: management challenges during pregnancy

Activity of ankylosing spondylitis in women within one year after childbirth

Treatment Patterns and Resource Utilization of Pregnant Women with Inflammatory Rheumatic Diseases or Psoriasis in Germany: A Claims Database Analysis

Contact Info

Product

Resources

About